Outside Milestone Date Sample Clauses

Outside Milestone Date. December 1, 2020, subject to extension for up to one hundred (100) days of Force Majeure, if applicable. Tenant’s Termination Expenses Cap: Twenty Million and 00/100 Dollars ($20,000,000.00) Remedy: Landlord shall update Tenant on the status of the achievement of the Outside Milestone during the Job Meetings (as defined in Section 4.4(B)) and from time to time on Tenant's request. Landlord shall give Tenant notice (“Outside Milestone Notice”) at such time as Landlord has achieved the Outside Milestone. (If Landlord has previously delivered a Fourth Milestone Notice, then an Outside Milestone Notice shall not be required.) If Landlord has not given Tenant the Outside Milestone Notice prior to the Outside Milestone Date, Tenant shall have the right to terminate the Lease upon written notice to Landlord given within thirty (30) days after the Outside Milestone Date, provided that, if Landlord achieves the Outside Milestone and delivers the Outside Milestone Notice within the thirty (30) day period after Landlord receives such termination notice, ▇▇▇▇▇▇’s termination notice shall be void. If Tenant has given such termination notice and the Outside Milestone is not achieved within said thirty (30) day cure period, then this Lease shall terminate. In the case of a termination based upon Landlord’s failure to achieve the Outside Milestone by the Outside Milestone Date: (i) Landlord shall, subject to the Tenant’s Termination Expenses Cap, reimburse Tenant for Tenant’s Termination Expenses (including, without limitation, Tenant's cost and expenses under Section 4.8(B)) within thirty (30) days after Tenant submits to Landlord reasonable evidence (e.g. paid invoices) of such costs and expenses, and (ii) neither party shall have any further obligation to the other party, except for the obligations of Tenant under Sections 4.4(L) with respect to the Tenant Design Contract, 13.1 (Tenant’s Indemnification), and 16.5 (Brokerage) and the obligations of Landlord under Sections 4.8(E)(2) (Final Accounting), 13.15 (Landlord’s Indemnification) and 16.5 (Brokerage). Any disputes arising under this Section 4.2 shall be submitted to arbitration under Section 4.9, and the arbitrator’s decision shall be conclusive and binding on the parties.
View Source

Related to Outside Milestone Date

  • Milestone Event Milestone Payment [***] [***]

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving (either itself or through the acts of a SUBLICENSEE) the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Sales Milestones On a Co-Co Product-by-Co-Co Product basis, Celgene shall make the following sales milestone payments to Jounce that are set forth below upon the first achievement by or on behalf of Celgene, its Affiliates or Sublicensees of the Sales Milestone Events set forth below with respect to sales of such Co-Co Product in the ROW Territory. [***] [***] [***] [***]

  • Milestone A principal event specified in the Contract Documents including the Material Completion and Occupancy Date and other events relating to an intermediate completion date or time.

  • Development Milestone Payments TriSalus shall pay (or cause to be paid) to Dynavax, in accordance with and subject to the terms of this Section 2.3, Section 2.4 and Section 6.4 (each such milestone, a “Development Milestone”, and each payment in respect thereof, a “Development Milestone Payment”): (i) Upon the successful completion by a Milestone Obligor after the Closing of a [**] study with respect to a Product using PEDD, a payment of [**] US Dollars ($[**]), with such Development Milestone Payment being payable only once (for purposes of the foregoing, successful completion means completion of such study in accordance with the plan for such study); (ii) For the first patient Dosed by a Milestone Obligor in each Phase 1 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iii) For the first patient Dosed by a Milestone Obligor in each Phase 2 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iv) For each Phase 2 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 2 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 2 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (v) For each Phase 3 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 3 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 3 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (vi) Upon receipt by a Milestone Obligor of each Regulatory Approval for any Product for any Indication in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (vii) Upon receipt by a Milestone Obligor for each Regulatory Approval of any Product for any Indication in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (viii) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vi) for receipt of such Regulatory Approval), regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; and (ix) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vii) for receipt of such Regulatory Approval), regardless ​ of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval.